MESO
HealthcareMesoblast Limited
$18.29
+$0.13 (+0.72%)
Jan 5, 2026
Price History (1Y)
Analysis
Mesoblast Limited is a biotechnology company in the healthcare sector with a market capitalization of $2.35 billion and approximately 81 employees. The company's industry classification is biotechnology. Financially, Mesoblast Limited has reported negative profitability metrics, including a gross margin of -132.2%, operating margin of -302.4%, and profit margin of 0.0%. The company also incurred significant net losses in the trailing twelve months, totaling $-102,142,000. In terms of returns, Mesoblast's return on equity is -19.0% and its return on assets is -5.4%. On a balance sheet level, the company has debt of $128.16 million and cash reserves of $161.55 million. Mesoblast Limited's valuation metrics are notable, with a forward P/E ratio of 107.59 and price to sales ratio of 136.87. The company's revenue growth over the past year is significant at 458.6%. However, its earnings growth rate is not available in the provided data.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Mesoblast Limited
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Visit website →Key Statistics
- Market Cap
- $2.35B
- P/E Ratio
- N/A
- 52-Week High
- $21.00
- 52-Week Low
- $9.61
- Avg Volume
- 214.54K
- Beta
- 0.95
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- Australia
- Employees
- 81